Raghad Alzahrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raghad Alzahrani has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abdulaziz H. Al Khzem
Department of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
4 shared publications - Hanin Alghamdi
College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
4 shared publications - Mansour S. Alturki
Department of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
4 shared publications - Mohamed Sayed Gomaa
Department of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
4 shared publications - Nada Tawfeeq
Department of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
4 shared publications - Thankhoe Abram Rants'O
Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA
4 shared publications
Latest Publications
- Open Access
- 27 January 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 174
Repurposing FDA-Approved Agents to Develop a Prototype Helicobacter pylori Shikimate Kinase (HPSK) Inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculations, MD Simulations, and DFT Analysis
Background/Objectives: Helicobacter pylori infects approximately half of the global population, causing chronic gastritis, peptic ulcers, and gastric cancer, a leading cause of cancer mortality. While current therapies face challenges from rising antibiotic resistance, particularly to clarithromycin, alongside treatment complexity and costs, the World Health Organization has prioritized the development of new antibiotics to combat this high-risk pathogen. In this study, we employed computer-aided drug design (CADD) methodologies, including molecular docking, Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) analysis, molecular dynamics (MD) simulations, and Density Functional Theory (DFT) calculations, to explore the potential repurposing of FDA-approved agents as inhibitors of Helicobacter pylori shikimate kinase (HpSK). Methods: Using the Glide module, the HTVS method was initially applied to screen 1615 FDA-approved agents followed by extra-precision (XP) docking for the obtained 111 hits. The obtained XP scores were used to confine the results to those hits with a score above the reference ligand, shikimate, score. This yielded 31 final hits with an XP score above −5.867. MM-GBSA calculations were performed on these top candidates and the reference ligand to refine the analysis and compounds’ prioritization. Results: The 31 compounds displayed binding free energy (ΔGbind) values ranging from 3.61 to −55.92 kcal/mol, with shikimate exhibiting a ΔGbind of −34.24 kcal/mol and 10 hits having a lower ΔGbind value. Out of these ten, three drugs—Dolutegravir, Cangrelor, and Isavuconazonium—were selected for further analysis based on their drug-like properties. Robust and stable binding profiles for both Isavuconazonium and Cangrelor were verified via molecular dynamics simulation. Additionally, Density Functional Theory (DFT) analysis was conducted, and the Highest Occupied Molecular Orbitals (HOMOs), Lowest Unoccupied Molecular Orbitals (LUMOs), and the energy gap (HLG) between them were calculated. All three drug candidates displayed lower HLG values than shikimate, suggesting higher reactivity and more efficient electronic transitions than the reference ligand. Conclusions: These findings suggest that the identified drugs, although not optimal for direct repurposing, would serve as promising leads against Helicobacter pylori shikimate kinase. These drugs could be valuable leads for experimental assessment and further optimization, particularly with no prototype yet identified. In terms of potential for clinical repurposing, the results point to diflunisal as a promising candidate for further testing.
- 27 January 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 174
Open AccessRepurposing FDA-Approved Agents to Develop a Prototype Helicobacter pylori Shikimate Kinase (HPSK) Inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculations, MD Simulations, and DFT Analysis
Background/Objectives: Helicobacter pylori infects approximately half of the global population, causing chronic gastritis, peptic ulcers, and gastric cancer, a leading cause of cancer mortality. While current therapies face challenges from rising antibiotic resistance, particularly to clarithromycin, alongside treatment complexity and costs, the World Health Organization has prioritized the development of new antibiotics to combat this high-risk pathogen. In this study, we employed computer-aided drug design (CADD) methodologies, including molecular docking, Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) analysis, molecular dynamics (MD) simulations, and Density Functional Theory (DFT) calculations, to explore the potential repurposing of FDA-approved agents as inhibitors of Helicobacter pylori shikimate kinase (HpSK). Methods: Using the Glide module, the HTVS method was initially applied to screen 1615 FDA-approved agents followed by extra-precision (XP) docking for the obtained 111 hits. The obtained XP scores were used to confine the results to those hits with a score above the reference ligand, shikimate, score. This yielded 31 final hits with an XP score above −5.867. MM-GBSA calculations were performed on these top candidates and the reference ligand to refine the analysis and compounds’ prioritization. Results: The 31 compounds displayed binding free energy (ΔGbind) values ranging from 3.61 to −55.92 kcal/mol, with shikimate exhibiting a ΔGbind of −34.24 kcal/mol and 10 hits having a lower ΔGbind value. Out of these ten, three drugs—Dolutegravir, Cangrelor, and Isavuconazonium—were selected for further analysis based on their drug-like properties. Robust and stable binding profiles for both Isavuconazonium and Cangrelor were verified via molecular dynamics simulation. Additionally, Density Functional Theory (DFT) analysis was conducted, and the Highest Occupied Molecular Orbitals (HOMOs), Lowest Unoccupied Molecular Orbitals (LUMOs), and the energy gap (HLG) between them were calculated. All three drug candidates displayed lower HLG values than shikimate, suggesting higher reactivity and more efficient electronic transitions than the reference ligand. Conclusions: These findings suggest that the identified drugs, although not optimal for direct repurposing, would serve as promising leads against Helicobacter pylori shikimate kinase. These drugs could be valuable leads for experimental assessment and further optimization, particularly with no prototype yet identified. In terms of potential for clinical repurposing, the results point to diflunisal as a promising candidate for further testing.
- Open Access
- 25 December 2024
- Published by MDPI AG in Preprints.org
Repurposing FDA-Approved Agents to Develop a Prototype Helicobacter Pylori Shikimate Kinase (HPSK) inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculation, MD Simulations, and DFT Analysis
Background/ Objectives: Helicobacter pylori infects approximately half of the global popu-lation, causing chronic gastritis, peptic ulcers, and gastric cancer, a leading cause of can-cer mortality. While current therapies face challenges from rising antibiotic resistance, particularly to clarithromycin, alongside treatment complexity and costs, the World Health Organization has prioritized the development of new antibiotics to combat this high-risk pathogen. In this study, we employed computer-aided drug design (CADD) methodologies, including molecular docking, Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) analysis, molecular dynamics (MD) simulations, and Density Functional Theory (DFT) calculations, to explore the potential repurposing of FDA-approved agents as inhibitors of Helicobacter pylori shikimate kinase (HpSK). Meth-ods: Using the Glide module, the HTVS method was initially applied to screen 1,615 FDA-followed by extra-precision (XP) docking for the obtained 111 hits. The obtained XP scores were used to confine the results to those hits with a score above the reference ligand, Shikimate, score. This yielded 31 final hits with an XP score above -5.867. MM-GBSA cal-culations were performed on these top candidates and the reference ligand to refine the analysis and compounds’ prioritization. Results: The 31 compounds displayed binding free energy (ΔGbind) values ranging from 3.61 to -55.92 kcal/mol, with shikimate exhibiting a ΔGbind of -34.24 kcal/mol and ten hits having lower ΔGbind value. Out of these ten, three drugs—Dolutegravir, Cangrelor, and Isavuconazonium—were selected for further analy-sis based on their drug-like properties. Robust and stable binding profiles for both Isavuconazonium and Cangrelor were verified via molecular dynamics simulation. Addi-tionally, Density Functional Theory (DFT) analysis was conducted, and the Highest Oc-cupied Molecular Orbitals (HOMO), Lowest Unoccupied Molecular Orbitals (LUMO), and the energy gap (HLG) between them were calculated. All three drug candidates displayed lower (HLG) values than shikimate, suggesting higher reactivity and more efficient elec-tronic transitions than the reference ligand. Conclusions: These findings suggest that the identified drugs, although not optimal for direct repurposing, would serve as promising leads against Helicobacter pylori shikimate kinase. These drugs could be valuable leads for experimental assessment and further optimization, particularly with no prototype yet has been identified. In terms of potential of clinical repurposing, the results pointed to diflunisal as a promising candidate for further testing.
- 25 December 2024
- Published by MDPI AG in Preprints.org
Open AccessRepurposing FDA-Approved Agents to Develop a Prototype Helicobacter Pylori Shikimate Kinase (HPSK) inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculation, MD Simulations, and DFT Analysis
Background/ Objectives: Helicobacter pylori infects approximately half of the global popu-lation, causing chronic gastritis, peptic ulcers, and gastric cancer, a leading cause of can-cer mortality. While current therapies face challenges from rising antibiotic resistance, particularly to clarithromycin, alongside treatment complexity and costs, the World Health Organization has prioritized the development of new antibiotics to combat this high-risk pathogen. In this study, we employed computer-aided drug design (CADD) methodologies, including molecular docking, Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) analysis, molecular dynamics (MD) simulations, and Density Functional Theory (DFT) calculations, to explore the potential repurposing of FDA-approved agents as inhibitors of Helicobacter pylori shikimate kinase (HpSK). Meth-ods: Using the Glide module, the HTVS method was initially applied to screen 1,615 FDA-followed by extra-precision (XP) docking for the obtained 111 hits. The obtained XP scores were used to confine the results to those hits with a score above the reference ligand, Shikimate, score. This yielded 31 final hits with an XP score above -5.867. MM-GBSA cal-culations were performed on these top candidates and the reference ligand to refine the analysis and compounds’ prioritization. Results: The 31 compounds displayed binding free energy (ΔGbind) values ranging from 3.61 to -55.92 kcal/mol, with shikimate exhibiting a ΔGbind of -34.24 kcal/mol and ten hits having lower ΔGbind value. Out of these ten, three drugs—Dolutegravir, Cangrelor, and Isavuconazonium—were selected for further analy-sis based on their drug-like properties. Robust and stable binding profiles for both Isavuconazonium and Cangrelor were verified via molecular dynamics simulation. Addi-tionally, Density Functional Theory (DFT) analysis was conducted, and the Highest Oc-cupied Molecular Orbitals (HOMO), Lowest Unoccupied Molecular Orbitals (LUMO), and the energy gap (HLG) between them were calculated. All three drug candidates displayed lower (HLG) values than shikimate, suggesting higher reactivity and more efficient elec-tronic transitions than the reference ligand. Conclusions: These findings suggest that the identified drugs, although not optimal for direct repurposing, would serve as promising leads against Helicobacter pylori shikimate kinase. These drugs could be valuable leads for experimental assessment and further optimization, particularly with no prototype yet has been identified. In terms of potential of clinical repurposing, the results pointed to diflunisal as a promising candidate for further testing.
- Open Access
- 23 December 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (12) , 727
Gallic Acid: A Potent Metabolite Targeting Shikimate Kinase in Acinetobacter baumannii
Background/Objectives: Acinetobacter baumannii is a highly multidrug-resistant pathogen resistant to almost all classes of antibiotics; new therapeutic strategies against this infectious agent are urgently needed. Shikimate kinase is an enzyme belonging to the shikimate pathway and has become a potential target for drug development. This work describes the search for Food and Drug Administration (FDA)-approved drugs and natural compounds, including gallic acid, that could be repurposed as selective shikimate kinase inhibitors by integrated computational and experimental approaches. Methods: Approaches to drug design using structure-based and ligand-based methodology, in-silico screening, molecular docking, and molecular dynamics for the study of both binding affinity and stability. Experimental Validation Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) on Acinetobacter baumannii and Enterococcus faecalis. Results/Conclusions: Among them, gallic acid, obtained from plants, proved to be the most promising compound that showed sufficient binding with shikimate kinase through computational studies. Gallic acid showed very good activity against Acinetobacter baumannii and Enterococcus faecalis in the MIC and MBC assay, respectively. Gallic acid exhibited better activity against Acinetobacter baumannii due to the overexpression of shikimate kinase. Gallic acid has emerged as a potential therapeutic candidate drug against A. baumannii infection and, therefore, as a strategy against the appearance of multidrug-resistant microorganisms. This study not only identifies a novel repurposing opportunity for gallic acid but also provides a comprehensive computational and experimental framework for accelerating antimicrobial drug discovery against multidrug-resistant pathogens.
- 23 December 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (12) , 727
Open AccessGallic Acid: A Potent Metabolite Targeting Shikimate Kinase in Acinetobacter baumannii
Background/Objectives: Acinetobacter baumannii is a highly multidrug-resistant pathogen resistant to almost all classes of antibiotics; new therapeutic strategies against this infectious agent are urgently needed. Shikimate kinase is an enzyme belonging to the shikimate pathway and has become a potential target for drug development. This work describes the search for Food and Drug Administration (FDA)-approved drugs and natural compounds, including gallic acid, that could be repurposed as selective shikimate kinase inhibitors by integrated computational and experimental approaches. Methods: Approaches to drug design using structure-based and ligand-based methodology, in-silico screening, molecular docking, and molecular dynamics for the study of both binding affinity and stability. Experimental Validation Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) on Acinetobacter baumannii and Enterococcus faecalis. Results/Conclusions: Among them, gallic acid, obtained from plants, proved to be the most promising compound that showed sufficient binding with shikimate kinase through computational studies. Gallic acid showed very good activity against Acinetobacter baumannii and Enterococcus faecalis in the MIC and MBC assay, respectively. Gallic acid exhibited better activity against Acinetobacter baumannii due to the overexpression of shikimate kinase. Gallic acid has emerged as a potential therapeutic candidate drug against A. baumannii infection and, therefore, as a strategy against the appearance of multidrug-resistant microorganisms. This study not only identifies a novel repurposing opportunity for gallic acid but also provides a comprehensive computational and experimental framework for accelerating antimicrobial drug discovery against multidrug-resistant pathogens.
- Open Access
- 15 November 2024
- Published by MDPI AG in Preprints.org
Targeting Shikimate Kinase in Acinetobacter baumannii: Gallic Acid as a Potent Inhibitory Metabolite from FDA-Approved Drug Screening
The current study identified certain FDA-approved drugs that could be repurposed as selective inhibitors against Acinetobacter baumannii shikimate kinase. Structure- and ligand-based drug design approaches have been integrated herein with extensive in-silico screening, molecular docking, and molecular dynamics studies, focusing on binding affinity and stability. Gallic acid, a plant-derived metabolite, has emerged as the most promising candidate, with significant binding interactions that are well supported by both computational analyses and experimental validation. MIC and MBC tests were conducted to examine their effectiveness against Acinetobacter baumannii and Enterococcus faecalis. Gallic acid demonstrated remarkable activity against the test microbial strains, presenting a promising therapeutic agent, especially given the high expression of shikimate kinase in Acinetobacter baumannii.
- 15 November 2024
- Published by MDPI AG in Preprints.org
Open AccessTargeting Shikimate Kinase in Acinetobacter baumannii: Gallic Acid as a Potent Inhibitory Metabolite from FDA-Approved Drug Screening
The current study identified certain FDA-approved drugs that could be repurposed as selective inhibitors against Acinetobacter baumannii shikimate kinase. Structure- and ligand-based drug design approaches have been integrated herein with extensive in-silico screening, molecular docking, and molecular dynamics studies, focusing on binding affinity and stability. Gallic acid, a plant-derived metabolite, has emerged as the most promising candidate, with significant binding interactions that are well supported by both computational analyses and experimental validation. MIC and MBC tests were conducted to examine their effectiveness against Acinetobacter baumannii and Enterococcus faecalis. Gallic acid demonstrated remarkable activity against the test microbial strains, presenting a promising therapeutic agent, especially given the high expression of shikimate kinase in Acinetobacter baumannii.